Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Vanguard International High Dividend Yield ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Vanguard International High Dividend Yield ETF trades at $100.51 (market cap $22.80B). The key difference: Vanguard International High Dividend Yield ETF is far larger — about 8× Dyne Therapeutics Inc. Common Stock's market cap, and Vanguard International High Dividend Yield ETF is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Vanguard International High Dividend Yield ETF for 51 Days on average.
| DYN | VYMI | |
|---|---|---|
Market Cap | $2.86B | $22.80B |
Volume | 3,341,579 | 740,346 |
Sector | Health | Broad Market / Factor |
52-Week High | $26.78 | $107.13 |
52-Week Low | $14.60 | $84.45 |
Typical Hold Time | 0 Days | 51 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
VYMI trades at $101.52, up 0.71% with a bearish technical signal from moving averages. The ETF shows strong institutional interest with Envestnet increasing holdings by 22% in Q2 2026. Recent news highlights VYMI's 29% one-year return and 3.61% dividend yield, outperforming peers with a 5-year average annual return of 14.13% according to Seeking Alpha on September 21, 2026.
The outlook remains positive with sector catalysts in financials, energy, and healthcare supporting dividend growth. Key risks include global market volatility and currency exposure. Analyst sentiment leans bullish with VYMI positioned as an attractive international dividend play amid rising global rates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →
